Daiichi Sankyo to launch olmesartan in Africa through Ranbaxy
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is planning to launch its antihypertensive olmesartan medoxomil in six African countries through the local operations of its Indian subsidiary Ranbaxy Laboratories.